IGC Pharma vs Ovid Therapeutics
IGC and OVID side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IGC and OVID compare
Ovid Therapeutics is the larger company, worth 27 times as much as IGC Pharma ($496M against $18.2M).
IGC Pharma grew revenue faster over the last twelve months (−15.4% versus −78.0% for Ovid Therapeutics).
IGC Pharma keeps more of each dollar of sales as profit, with a net margin of −702% compared with −2971% at Ovid Therapeutics.
Ovid Therapeutics scores higher on the StockData Score (9 against 2 for IGC Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IGC | OVID |
|---|---|---|
| Size and price | ||
| Market cap | $18.2M | $496M |
| Share price | $0.176 | $2.54 |
| Change, 1 year | −51.9% | 92.4% |
| Change, 5 years | −87.7% | −26.2% |
| Beta (5Y) | 0.59 | 1.22 |
| Employees | 67 | 23 |
| StockData Score | ||
| Total score | 2 | 9 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 16.2× (better) | 342× |
| P/B | 2.8× | 2.5× (better) |
| Fair value | $0.161 | – |
| Margin of safety | −9.1% | – |
| Growth | ||
| Revenue growth (TTM) | −15.4% (better) | −78.0% |
| Revenue growth, 5Y average | – | −10.5% |
| Profitability | ||
| Gross margin | 21.9% | – |
| Operating margin | −987% (better) | −4700% |
| Net margin | −702% (better) | −2971% |
| Return on equity | −113% | −35.4% (better) |
| Return on invested capital | −136% (better) | −191% |
| Financial health | ||
| Debt / equity | 0.02 (better) | 0.00 |
| Current ratio | 0.42 | 11.97 (better) |
| Altman Z-score | −19.52 | 9.96 (better) |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 5.1% | 75.3% |
| Held by insiders | 13.2% | 13.6% |
| Insider net buying, 12 months | – | −$29.3K |
| Short interest, % of float | 0.44% | 10.8% |
Go deeper
- IGC stock overview
- IGC income statement
- IGC valuation and score
- OVID stock overview
- OVID income statement
- OVID valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.